This study conducted a systematic review and meta-analysis but did not report results, aiming to clarify the unclear association between female pattern hair loss and polycystic ovary syndrome, along with potential links to altered fertility factors.
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” This study reports that using 5-alpha reductase inhibitors is associated with a 31% increased risk of depression, highlighting that the choice of comparator group significantly affects study results.
August 2025 in “Lasers in Medical Science” In this study, the combination of low-level laser therapy and topical minoxidil was found to improve hair density and diameter more effectively than minoxidil alone in treating androgenic alopecia, with similar safety profiles observed in both groups.
In this study, topical and intralesional vitamin D3 and its analogs were found to be effective and safe treatments for mild-to-moderate alopecia areata, achieving a 53.75% success rate, though intralesional vitamin D3 was less effective than other treatments like corticosteroids.
July 2025 in “Biomolecules” This systematic review found that topical adenosine may increase hair thickness and density while reducing hair loss, but the strength of evidence is low due to issues with trial design and sample size.
July 2025 in “Journal of Investigative Dermatology” Probiotics significantly reduce the severity of atopic dermatitis.
July 2025 in “Frontiers in Medicine” In this systematic review and meta-analysis, the authors examined single-spin versus double-spin centrifugation protocols for PRP in patients with androgenic alopecia and found no significant difference in platelet concentration, hair density, or hair types between the protocols.
June 2025 in “Journal of Cosmetic Dermatology” This study found that among various treatments for male androgenetic alopecia, dutasteride 0.5 mg/day was the most effective option overall. Additionally, among FDA-approved treatments, topical minoxidil 5% was the most effective topical therapy, and finasteride 1 mg/day was the most effective oral therapy.
June 2025 in “Frontiers in Pharmacology” This systematic review and meta-analysis found that oral minoxidil improved hair loss symptoms in many patients, with significant improvement in 35%, but 27% experienced adverse events, highlighting the need for further research to confirm its safety and efficacy.
May 2025 in “Journal of International Medical Research” In this study, micrografting technology was found to potentially shorten healing time compared to other grafting techniques, especially in treating burns, though results showed high heterogeneity and a risk of bias.
April 2025 in “Annals of Medicine” This study assessed the combination of compound glycyrrhizin and conventional treatments for alopecia areata and found it effective for promoting hair regrowth while being safe with mild adverse effects, based on a systematic review and meta-analysis of randomized controlled trials.
April 2025 in “European Psychiatry” This systematic review and meta-analysis found that mood stabilizers used for bipolar disorder, such as lithium, valproate, carbamazepine, and lamotrigine, resulted in varying prevalence of dermatologic side effects, with lamotrigine showing the highest rash incidence, while severe reactions were rare.
March 2025 in “Archives of Dermatological Research” This study found that combined microneedling with minoxidil significantly improved hair count and diameter in patients with androgenetic alopecia, although more mild adverse events were reported compared to minoxidil alone.
January 2025 in “Journal of Dermatological Treatment” This systematic review and meta-analysis found that adding low-level laser therapy to minoxidil treatment for androgenic alopecia does not significantly enhance hair count or diameter compared to using minoxidil alone.
December 2024 in “Journal of Clinical Medicine” This study reported that both 5% topical and oral minoxidil achieved an 82% hair regrowth response rate in alopecia areata patients, but 5% topical minoxidil was more effective than lower concentrations.
December 2024 in “Frontiers in Surgery” This systematic review found no existing studies evaluating the effectiveness of waxing and mechanical epilation as methods of preoperative hair removal to reduce surgical site infections, highlighting a potential area for future research.
October 2024 in “Frontiers in Nutrition” This study found that patients with alopecia, particularly alopecia areata and female pattern hair loss, often have vitamin D deficiency, suggesting that screening for vitamin D could benefit these patients.
August 2024 in “Skin Research and Technology” In this systematic review and meta-analysis, PRP therapy significantly improved hair density and thickness for women experiencing hair loss, with mild and transient adverse effects, suggesting potential tailored treatment protocols based on dosage, injection duration, and ethnicity.
July 2024 in “Anais Brasileiros de Dermatologia” PRP injections can increase hair density in people with androgenic alopecia.
May 2024 in “European urology focus” In this systematic review and meta-analysis, the authors found no statistically significant association between the use of 5α-reductase inhibitors and the risk of depression or suicide among over two million studied patients.
April 2024 in “Frontiers in pharmacology” This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.
In this systematic review, researchers observed that Toxoplasma gondii infection is associated with alterations in testosterone levels, generally increasing in humans but showing mixed effects in animals, highlighting a complex relationship that warrants further investigation.
November 2023 in “Journal of Cosmetic Dermatology” This study found that patients with non-scarring alopecia, such as androgenetic alopecia and female pattern hair loss, have lower serum levels of 25-hydroxyvitamin D and a higher incidence of vitamin D deficiency compared to healthy controls.
The study aims to find the most effective treatments for male pattern baldness.
October 2023 in “The Cochrane library” This review identified that baricitinib increases both short- and long-term hair regrowth in patients with alopecia areata compared to placebo, but found inconclusive results for serious adverse effects, while evidence for other treatments remains very uncertain.
In this study, researchers examined a document submitted by Jakeline Ortega related to Joandele Cristina da Silva Barcelos, but results or specific findings are not reported in the abstract.
September 2023 in “Archives of Dermatological Research” Using minoxidil with microneedling increases hair count for hair loss without serious side effects.
August 2023 in “Skin Research and Technology” This study found that platelet-rich plasma is effective and safe for treating chronic wounds, particularly diabetic and venous ulcers, and vitiligo, without increasing the risk of infection.
August 2023 in “Psychology, Health & Medicine” This systemic review and meta-analysis found that men with androgenetic alopecia generally experience moderate impacts on quality of life, but limited evidence of severe effects on mental health.
In a systematic review and meta-analysis, this study reported that oral spironolactone showed a 56.60% overall improvement in female pattern hair loss, with better results in combination therapy, but emphasized the need for more research due to varied treatment responses and adverse event rates.